Second-tier testing for 21-hydroxylase deficiency in the Netherlands; a newborn screening pilot study.

Stroek, KevinRuiter, Anvan der Linde, AnneliekeAckermans, MarietteBouva, Marelle JEngel, HenkJakobs, BernadetteKemper, Evelien Avan den Akker, Erica L Tvan Albada, Mirjam EBocca, GianniFinken, Martijn J JHannema, Sabine EHoudijk, E C A Miekevan der Kamp, Hetty Jvan Tellingen, Veravan Trotsenburg, A S PaulZwaveling-Soonawala, NitashBosch, Annet Mde Jonge, RobertHeijboer, Annemieke CClaahsen-van der Grinten, Hedi LBoelen, Anita2021-07-192021-07-192021-06-253417108510.1210/clinem/dgab464http://hdl.handle.net/10029/625107en© The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.info:eu-repo/semantics/closedAccessSecond-tier testing for 21-hydroxylase deficiency in the Netherlands; a newborn screening pilot study.Article1945-7197J Clin Endocrinol Metab 2021; 106(11):e4487-e4496